Global Pharmaceutical Contract Manufacturing Market Research and Forecast 2018-2023
The major players operating in the pharmaceutical industry consider outsourcing of the product manufacturing to contract manufacturing organizations. The contract manufacturers provide timely and cost-effective services, which in turn, enable the market players to focus on their core competencies. A pharmaceutical contract manufacturer offers comprehensive services to the clients ranging from drug development to the packaging of the products. Some of the services offered by contract manufacturers to their clients can be divided into two main categories: primary manufacturing and secondary manufacturing. The primary manufacturing mainly involves the synthesis of the bulk active pharmaceutical ingredients (API); however, the secondary manufacturing includes the formulation of bulk drug substances into the final drug products such as pills, topical formulations, and types of injectables.
Major factors contributing to the growth of the global pharmaceutical contract manufacturing market include. Increasing trend of outsourcing of healthcare services. In addition, patent cliff is another significant factor contributing in the market growth. The ongoing patent expiry of many blockbuster drugs coupled with decreasing profit margins on branded drugs, is forcing most healthcare companies to outsource manufacturing to control costs. Additionally, patent cliffs have cut sales revenue of many branded medications and forced drug makers to consider outsourcing manufacturing to enable control production costs. However, stringent government regulations hinder the market growth. Moreover, rising demand for low cost services and increasing drug discovery is expected to fuel the market growth in the near future.
The pharmaceutical contract manufacturing market can be segmented on the basis of category, type, product, route of administration, and services. On the basis of category, the market is divided as human-based drugs and animals-based drugs. Based on type, the market is segmented into sterile manufacturing and non-sterile manufacturing. Based on the product, the market is bifurcated into OTC drugs, API, finished dosage forms include solid dose, liquid dose and injectable dose, and others such as nutritional products and packaging. Based on the services, the market is sub-divided as manufacturing services, non-clinical services and research and development. Among services, manufacturing segment is expected to be the highest revenue generating segment owing to growing medical device manufacturing. The growth of medical device manufacturing in emerging economies such as the US, China, Japan and India is expected to boost the manufacturing services segment.
The global pharmaceutical contract manufacturing market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America is expected to dominating the healthcare and life science market due to increasing number of research and development in this region. The US has major share in the global healthcare and life science market due to the increasing healthcare expenditure that in turn fuels the pharmaceutical contract manufacturing market. Europe has considerable market share in the global pharmaceutical contract manufacturing market. The North American market is projected to remain dominant in the global Pharmaceutical Contract Manufacturing market over the forecast period.
Some of the key players operating in the global pharmaceutical contract manufacturing market are AbbVie Inc., Aenova Group GmbH, Aurobindo Pharma Limited, Jubilant Life Sciences Ltd., Lonza AG and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For instance, Aenova Group in November 2017, expanded its animal-health production and develops manufacturing areas for solids veterinary pharmaceutical in Latina. In addition, in September 2017, the company expanded its site in Romania for increasing the production capacity for soft gelatin capsule. The company invested about $11.6 million for the expansion of site.
RESEARCH METHODOLOGY
The market study of pharmaceutical contract manufacturing market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
MARKET SEGMENTATION:
Global Pharmaceutical Contract Manufacturing market is segmented on the basis of regional outlook and following segments:
Major factors contributing to the growth of the global pharmaceutical contract manufacturing market include. Increasing trend of outsourcing of healthcare services. In addition, patent cliff is another significant factor contributing in the market growth. The ongoing patent expiry of many blockbuster drugs coupled with decreasing profit margins on branded drugs, is forcing most healthcare companies to outsource manufacturing to control costs. Additionally, patent cliffs have cut sales revenue of many branded medications and forced drug makers to consider outsourcing manufacturing to enable control production costs. However, stringent government regulations hinder the market growth. Moreover, rising demand for low cost services and increasing drug discovery is expected to fuel the market growth in the near future.
The pharmaceutical contract manufacturing market can be segmented on the basis of category, type, product, route of administration, and services. On the basis of category, the market is divided as human-based drugs and animals-based drugs. Based on type, the market is segmented into sterile manufacturing and non-sterile manufacturing. Based on the product, the market is bifurcated into OTC drugs, API, finished dosage forms include solid dose, liquid dose and injectable dose, and others such as nutritional products and packaging. Based on the services, the market is sub-divided as manufacturing services, non-clinical services and research and development. Among services, manufacturing segment is expected to be the highest revenue generating segment owing to growing medical device manufacturing. The growth of medical device manufacturing in emerging economies such as the US, China, Japan and India is expected to boost the manufacturing services segment.
The global pharmaceutical contract manufacturing market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America is expected to dominating the healthcare and life science market due to increasing number of research and development in this region. The US has major share in the global healthcare and life science market due to the increasing healthcare expenditure that in turn fuels the pharmaceutical contract manufacturing market. Europe has considerable market share in the global pharmaceutical contract manufacturing market. The North American market is projected to remain dominant in the global Pharmaceutical Contract Manufacturing market over the forecast period.
Some of the key players operating in the global pharmaceutical contract manufacturing market are AbbVie Inc., Aenova Group GmbH, Aurobindo Pharma Limited, Jubilant Life Sciences Ltd., Lonza AG and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For instance, Aenova Group in November 2017, expanded its animal-health production and develops manufacturing areas for solids veterinary pharmaceutical in Latina. In addition, in September 2017, the company expanded its site in Romania for increasing the production capacity for soft gelatin capsule. The company invested about $11.6 million for the expansion of site.
RESEARCH METHODOLOGY
The market study of pharmaceutical contract manufacturing market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
- Financial reports of companies involved in the market
- Authentic Public Databases such as American College of Rheumatology, American Association for Clinical Chemistry (AACC), and American Autoimmune Related Diseases Association (AARDA), among others.
- Whitepapers, research-papers, and news blogs
- Company websites and their product catalogue
- Supplier Websites such as Alibaba, amazon for pricing analysis
MARKET SEGMENTATION:
Global Pharmaceutical Contract Manufacturing market is segmented on the basis of regional outlook and following segments:
- Global Pharmaceutical Contract Manufacturing Market Research and Analysis, By Category
- Global Pharmaceutical Contract Manufacturing Market Research and Analysis, By Type
- Global Pharmaceutical Contract Manufacturing Market Research and Analysis, By Product
- Global Pharmaceutical Contract Manufacturing Market Research and Analysis, By Services
- Global Pharmaceutical Contract Manufacturing Market Research and Analysis, By Region
- Comprehensive research methodology of global Pharmaceutical Contract Manufacturing market.
- This report also includes detailed and extensive market overview with key analyst insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global Pharmaceutical Contract Manufacturing market.
- Insights about market determinants which are stimulating the global Pharmaceutical Contract Manufacturing market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. VALUE CHAIN OF PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
2.3. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.3.1. KEY FINDINGS
2.3.2. RECOMMENDATION
2.3.3. CONCLUSION
2.4. RULES & REGULATIONS
2.4.1.1. UNITED STATES
2.4.1.2. EUROPEAN UNION
2.4.1.3. CHINA
2.4.1.4. JAPAN
2.4.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISING TRENDS OF OUTSOURCING OF HEALTHCARE SERVICES
3.1.2. PATENT CLIFFS DRIVING PHARMACEUTICAL CONTRACT MANUFACTURING
3.1.3. INCREASING PRESSURE TO MINIMIZE HEALTHCARE COST
3.1.4. AVAILABILITY OF SKILLED WORKFORCE FOR LOW COST
3.1.5. INCREASING DEMAND FOR DRUGS AND MEDICAL DEVICES COUPLED WITH RISING GERIATRIC POPULATION
3.2. RESTRAINTS
3.2.1. INCREASING RISK REGARDING OUTSOURCING
3.2.2. STRINGENT GOVERNMENT REGULATIONS
3.3. OPPORTUNITIES
3.3.1. INCREASING DRUG DISCOVERY AND COMPLEX CLINICAL TRIAL PROTOCOLS FUELS THE PHARMACEUTICAL OUTSOURCING
3.3.2. RISING DEMAND FOR LOW COST SERVICES
3.3.3. DOMINANCE OF MARKET CONTIBUTOR SUCH AS INDIA
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY CATEGORY
4.1.1. HUMAN BASED DRUGS
4.1.2. ANIMALS BASED DRUGS
4.2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE
4.2.1. STERILE MANUFACTURING
4.2.2. NON-STERILE MANUFACTURING
4.3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY PRODUCT
4.3.1. OVER-THE-COUNTER (OTC) DRUGS
4.3.2. ACTIVE PHARMACEUTICAL INGREDIENTS (API)
4.3.3. FINISHED DOSAGE FORMULATION (SOLID DOSE, LIQUID DOSE AND INJECTABLE DOSE)
4.3.4. OTHERS (NUTRITIONAL PRODUCTS AND PACKAGING)
4.4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING BY SERVICES
4.4.1. MANUFACTURING SERVICES
4.4.2. NON-CLINICAL SERVICES SUCH AS SUPPLY CHAIN MANAGEMENT
4.4.3. RESEARCH AND DEVELOPMENT
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. TAIWAN
6.3.4. JAPAN
6.3.5. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ABBVIE INC.
7.2. AENOVA GROUP GMBH
7.3. AESICA PHARMACEUTICALS LIMITED
7.4. AJINOMOTO ALTHEA, INC.
7.5. ALLEGIANT HEALTHCARE INC.
7.6. ALMAC GROUP
7.7. AURENA LABORATORIES AB
7.8. AUROBINDO PHARMA LIMITED
7.9. BAXTER INTERNATIONAL INC.
7.10. BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD.
7.11. BLUEGUM PHARMACEUTICALS PTY LTD
7.12. BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
7.13. CADENCE DEVICE, INC.
7.14. CATALENT, INC.
7.15. CHIP STAR TECHNOLOGY, LLC
7.16. CHUNGHWA CHEMICAL & PHARMACEUTICAL CO., LTD.
7.17. CIRON, INC.
7.18. CONFAB LABORATORIES INC.
7.19. CORDEN PHARMA INTERNATIONAL GMBH
7.20. DAITO PHARMACEUTICAL CO., LTD.
7.21. DELPHARM SAS
7.22. DISHMAN GROUP
7.23. DIVIS LABORATORIES LTD.
7.24. DOUGLAS MANUFACTURING LTD.
7.25. DPT LABORATORIES, LTD.
7.26. DR. REDDY’S LABORATORIES LTD.
7.27. DRAVON MEDICAL INC.
7.28. EAST WEST MANUFACTURING, LLC
7.29. ESTEVE QUÍMICA, S.A.
7.30. EUTICALS S.P.A.
7.31. EVER NEURO PHARMA GMBH
7.32. EVONIK INDUSTRIES AG
7.33. FAMAR S.A.
7.34. FAREVA GROUP
7.35. FERAMED B.V.
7.36. FINECURE PHARMACEUTICALS LTD.
7.37. GALENA PHARMA OY
7.38. GRACURE PHARMACEUTICALS LTD.
7.39. HISUN PHARMACEUTICALS USA INC
7.40. HTI PLASTICS, INC.
7.41. JUBILANT LIFE SCIENCES LTD.
7.42. KORTEN PHARMACEUTICALS PVT. LTD.
7.43. LEE BIOSOLUTIONS, INC.
7.44. LOGOS PHARMA
7.45. LONZA AG
7.46. MCGUFF PHARMACEUTICALS, INC.
7.47. MIKART, INC.
7.48. NEEDLETECH PRODUCTS, INC.
7.49. NEXTPHARMA TECHNOLOGIES HOLDING LIMITED
7.50. NEXTPHASE MEDICAL DEVICES, LLC.
7.51. NIKOL FORMULATION PVT. LTD.
7.52. NIPRO GROUP
7.53. NISSHA CO., LTD.
7.54. NORTECH SYSTEMS INC.
7.55. ONYX SCIENTIFIC LIMITED
7.56. PATHEON N.V.
7.57. PFIZER CENTREONE
7.58. PHARMASYNTH FORMULATIONS LIMITED
7.59. PHOENIX DEVENTURES INC.
7.60. PIRAMAL PHARMA SOLUTIONS INC.
7.61. PROVET SA
7.62. RADICO REMEDIES
7.63. RECIPHARM AB
7.64. REFIT ANIMAL CARE
7.65. SAIN MEDICAMENTS PVT. LTD.
7.66. SHANDONG XINHUA PHARMACEUTICAL CO., LTD.
7.67. SIEGFRIED AG
7.68. SMC LTD.
7.69. STERLING PHARMACEUTICAL SERVICES LLC
7.70. SOPHARMA AD
7.71. STASON PHARMACEUTICALS, INC.
7.72. SYNECCO LTD.
7.73. SYNOKEM PHARMA LIMITED
7.74. TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA API)
7.75. UNIVET VETERINARY PHARMACEUTICAL COMPANY
7.76. VETTER PHARMA INTERNATIONAL GMBH
7.77. WEST PHARMACEUTICAL SERVICES, INC.
7.78. YASH PHARMA LABORATORIES PVT. LTD.
7.79. ZOETIS, INC.
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. VALUE CHAIN OF PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
2.3. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.3.1. KEY FINDINGS
2.3.2. RECOMMENDATION
2.3.3. CONCLUSION
2.4. RULES & REGULATIONS
2.4.1.1. UNITED STATES
2.4.1.2. EUROPEAN UNION
2.4.1.3. CHINA
2.4.1.4. JAPAN
2.4.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISING TRENDS OF OUTSOURCING OF HEALTHCARE SERVICES
3.1.2. PATENT CLIFFS DRIVING PHARMACEUTICAL CONTRACT MANUFACTURING
3.1.3. INCREASING PRESSURE TO MINIMIZE HEALTHCARE COST
3.1.4. AVAILABILITY OF SKILLED WORKFORCE FOR LOW COST
3.1.5. INCREASING DEMAND FOR DRUGS AND MEDICAL DEVICES COUPLED WITH RISING GERIATRIC POPULATION
3.2. RESTRAINTS
3.2.1. INCREASING RISK REGARDING OUTSOURCING
3.2.2. STRINGENT GOVERNMENT REGULATIONS
3.3. OPPORTUNITIES
3.3.1. INCREASING DRUG DISCOVERY AND COMPLEX CLINICAL TRIAL PROTOCOLS FUELS THE PHARMACEUTICAL OUTSOURCING
3.3.2. RISING DEMAND FOR LOW COST SERVICES
3.3.3. DOMINANCE OF MARKET CONTIBUTOR SUCH AS INDIA
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY CATEGORY
4.1.1. HUMAN BASED DRUGS
4.1.2. ANIMALS BASED DRUGS
4.2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE
4.2.1. STERILE MANUFACTURING
4.2.2. NON-STERILE MANUFACTURING
4.3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY PRODUCT
4.3.1. OVER-THE-COUNTER (OTC) DRUGS
4.3.2. ACTIVE PHARMACEUTICAL INGREDIENTS (API)
4.3.3. FINISHED DOSAGE FORMULATION (SOLID DOSE, LIQUID DOSE AND INJECTABLE DOSE)
4.3.4. OTHERS (NUTRITIONAL PRODUCTS AND PACKAGING)
4.4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING BY SERVICES
4.4.1. MANUFACTURING SERVICES
4.4.2. NON-CLINICAL SERVICES SUCH AS SUPPLY CHAIN MANAGEMENT
4.4.3. RESEARCH AND DEVELOPMENT
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. TAIWAN
6.3.4. JAPAN
6.3.5. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ABBVIE INC.
7.2. AENOVA GROUP GMBH
7.3. AESICA PHARMACEUTICALS LIMITED
7.4. AJINOMOTO ALTHEA, INC.
7.5. ALLEGIANT HEALTHCARE INC.
7.6. ALMAC GROUP
7.7. AURENA LABORATORIES AB
7.8. AUROBINDO PHARMA LIMITED
7.9. BAXTER INTERNATIONAL INC.
7.10. BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD.
7.11. BLUEGUM PHARMACEUTICALS PTY LTD
7.12. BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
7.13. CADENCE DEVICE, INC.
7.14. CATALENT, INC.
7.15. CHIP STAR TECHNOLOGY, LLC
7.16. CHUNGHWA CHEMICAL & PHARMACEUTICAL CO., LTD.
7.17. CIRON, INC.
7.18. CONFAB LABORATORIES INC.
7.19. CORDEN PHARMA INTERNATIONAL GMBH
7.20. DAITO PHARMACEUTICAL CO., LTD.
7.21. DELPHARM SAS
7.22. DISHMAN GROUP
7.23. DIVIS LABORATORIES LTD.
7.24. DOUGLAS MANUFACTURING LTD.
7.25. DPT LABORATORIES, LTD.
7.26. DR. REDDY’S LABORATORIES LTD.
7.27. DRAVON MEDICAL INC.
7.28. EAST WEST MANUFACTURING, LLC
7.29. ESTEVE QUÍMICA, S.A.
7.30. EUTICALS S.P.A.
7.31. EVER NEURO PHARMA GMBH
7.32. EVONIK INDUSTRIES AG
7.33. FAMAR S.A.
7.34. FAREVA GROUP
7.35. FERAMED B.V.
7.36. FINECURE PHARMACEUTICALS LTD.
7.37. GALENA PHARMA OY
7.38. GRACURE PHARMACEUTICALS LTD.
7.39. HISUN PHARMACEUTICALS USA INC
7.40. HTI PLASTICS, INC.
7.41. JUBILANT LIFE SCIENCES LTD.
7.42. KORTEN PHARMACEUTICALS PVT. LTD.
7.43. LEE BIOSOLUTIONS, INC.
7.44. LOGOS PHARMA
7.45. LONZA AG
7.46. MCGUFF PHARMACEUTICALS, INC.
7.47. MIKART, INC.
7.48. NEEDLETECH PRODUCTS, INC.
7.49. NEXTPHARMA TECHNOLOGIES HOLDING LIMITED
7.50. NEXTPHASE MEDICAL DEVICES, LLC.
7.51. NIKOL FORMULATION PVT. LTD.
7.52. NIPRO GROUP
7.53. NISSHA CO., LTD.
7.54. NORTECH SYSTEMS INC.
7.55. ONYX SCIENTIFIC LIMITED
7.56. PATHEON N.V.
7.57. PFIZER CENTREONE
7.58. PHARMASYNTH FORMULATIONS LIMITED
7.59. PHOENIX DEVENTURES INC.
7.60. PIRAMAL PHARMA SOLUTIONS INC.
7.61. PROVET SA
7.62. RADICO REMEDIES
7.63. RECIPHARM AB
7.64. REFIT ANIMAL CARE
7.65. SAIN MEDICAMENTS PVT. LTD.
7.66. SHANDONG XINHUA PHARMACEUTICAL CO., LTD.
7.67. SIEGFRIED AG
7.68. SMC LTD.
7.69. STERLING PHARMACEUTICAL SERVICES LLC
7.70. SOPHARMA AD
7.71. STASON PHARMACEUTICALS, INC.
7.72. SYNECCO LTD.
7.73. SYNOKEM PHARMA LIMITED
7.74. TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA API)
7.75. UNIVET VETERINARY PHARMACEUTICAL COMPANY
7.76. VETTER PHARMA INTERNATIONAL GMBH
7.77. WEST PHARMACEUTICAL SERVICES, INC.
7.78. YASH PHARMA LABORATORIES PVT. LTD.
7.79. ZOETIS, INC.
LIST OF TABLES
TABLE 1 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL HUMAN BASED DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL ANIMALS BASED DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL STERILE MANUFACTURING MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL NON-STERILE MANUFACTURING MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL OTC DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL API MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL FINISHED DOSAGE FORMULATION MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL NON-CLINICAL SERVICES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 GLOBAL RESEARCH AND DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 16 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
TABLE 17 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 18 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 19 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 20 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 21 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
TABLE 22 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 23 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 24 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 25 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 26 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
TABLE 27 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 28 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 29 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 30 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 31 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
TABLE 32 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 33 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 34 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 35 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
TABLE 1 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL HUMAN BASED DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL ANIMALS BASED DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL STERILE MANUFACTURING MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL NON-STERILE MANUFACTURING MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL OTC DRUGS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL API MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL FINISHED DOSAGE FORMULATION MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL MANUFACTURING SERVICES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL NON-CLINICAL SERVICES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 GLOBAL RESEARCH AND DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 16 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
TABLE 17 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 18 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 19 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 20 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 21 NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
TABLE 22 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 23 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 24 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 25 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 26 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
TABLE 27 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 28 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 29 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 30 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 31 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
TABLE 32 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2017-2023 ($ MILLION)
TABLE 33 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 34 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2017-2023 ($ MILLION)
TABLE 35 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY CATEGORY, 2017 VS 2023 (%)
FIGURE 2 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY TYPE, 2017 VS 2023 (%)
FIGURE 3 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY PRODUCT, 2017 VS 2023 (%)
FIGURE 4 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY SERVICES, 2017 VS 2023 (%)
FIGURE 5 US PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 UK PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 ROE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 14 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 15 TAIWAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 17 ROAPAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 18 REST OF THE WORLD PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 1 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY CATEGORY, 2017 VS 2023 (%)
FIGURE 2 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY TYPE, 2017 VS 2023 (%)
FIGURE 3 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY PRODUCT, 2017 VS 2023 (%)
FIGURE 4 GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY SERVICES, 2017 VS 2023 (%)
FIGURE 5 US PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 UK PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 ROE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 14 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 15 TAIWAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 17 ROAPAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 18 REST OF THE WORLD PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
